108 related articles for article (PubMed ID: 24669387)
21. NSAID trials and the choice of comparators--questions of public health importance.
Psaty BM; Weiss NS
N Engl J Med; 2007 Jan; 356(4):328-30. PubMed ID: 17251528
[No Abstract] [Full Text] [Related]
22. Tolerance to COX-2 inhibitors in children with hypersensitivity to nonsteroidal anti-inflammatory drugs.
Corzo JL; Zambonino MA; Muñoz C; Mayorga C; Requena G; Urda A; Gallego C; Blanca M; Torres MJ
Br J Dermatol; 2014 Mar; 170(3):725-9. PubMed ID: 24116718
[TBL] [Abstract][Full Text] [Related]
23. [Coronary risks with NSAID and coxibs. The end of hysteria].
Einecke D
MMW Fortschr Med; 2006 Nov; 148(48):10, 12. PubMed ID: 17615760
[No Abstract] [Full Text] [Related]
24. Safety of etoricoxib in patients with reactions to NSAIDs.
Quercia O; Emiliani F; Foschi FG; Stefanini GF
J Investig Allergol Clin Immunol; 2008; 18(3):163-7. PubMed ID: 18564626
[TBL] [Abstract][Full Text] [Related]
25. Etoricoxib-induced toxic epidermal necrolysis.
Moutran R; Maatouk I; Hélou J
Int J Dermatol; 2014 Apr; 53(4):e275-7. PubMed ID: 23879726
[No Abstract] [Full Text] [Related]
26. [Non-selective NSAIDs and coxibs: what are myths, what are facts?].
MMW Fortschr Med; 2013 Jun; 155(12):56-7. PubMed ID: 23923320
[No Abstract] [Full Text] [Related]
27. Treatment with paracetamol, ketorolac or etoricoxib did not hinder alveolar bone healing: a histometric study in rats.
Fracon RN; Teófilo JM; Moris IC; Lamano T
J Appl Oral Sci; 2010 Dec; 18(6):630-4. PubMed ID: 21308296
[TBL] [Abstract][Full Text] [Related]
28. Fixed drug eruption caused by etoricoxib--2 cases confirmed by patch testing.
Andrade P; Gonçalo M
Contact Dermatitis; 2011 Feb; 64(2):118-20. PubMed ID: 21210830
[No Abstract] [Full Text] [Related]
29. Etoricoxib-induced erythema-multiforme-like eruption.
Thirion L; Nikkels AF; Piérard GE
Dermatology; 2008; 216(3):227-8. PubMed ID: 18182814
[TBL] [Abstract][Full Text] [Related]
30. Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study.
Andersohn F; Schade R; Suissa S; Garbe E
Stroke; 2006 Jul; 37(7):1725-30. PubMed ID: 16728684
[TBL] [Abstract][Full Text] [Related]
31. Short-term tolerability of etoricoxib in patients with cutaneous hypersensitivity reactions to nonsteroidal anti-inflammatory drugs.
Nettis E; Colanardi MC; Ferrannini A; Vacca A; Tursi A
Ann Allergy Asthma Immunol; 2005 Nov; 95(5):438-42. PubMed ID: 16312166
[TBL] [Abstract][Full Text] [Related]
32. Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial.
Baraf HS; Fuentealba C; Greenwald M; Brzezicki J; O'Brien K; Soffer B; Polis A; Bird S; Kaur A; Curtis SP;
J Rheumatol; 2007 Feb; 34(2):408-20. PubMed ID: 17304660
[TBL] [Abstract][Full Text] [Related]
33. Blood pressure and cardiovascular outcomes in patients taking nonsteroidal antiinflammatory drugs.
Krum H; Swergold G; Gammaitoni A; Peloso PM; Smugar SS; Curtis SP; Brater DC; Wang H; Kaur A; Laine L; Weir MR; Cannon CP
Cardiovasc Ther; 2012 Dec; 30(6):342-50. PubMed ID: 21884017
[TBL] [Abstract][Full Text] [Related]
34. [3 questions about gastrointestinal risk. Are coxibs here clearly better than NSAID?]].
Krüger K
MMW Fortschr Med; 2006 Nov; 148(48):12. PubMed ID: 17615761
[No Abstract] [Full Text] [Related]
35. Fixed drug eruption by etoricoxib confirmed by patch test.
Sousa AS; Cardoso JC; Gouveia MP; Gameiro AR; Teixeira VB; Gonçalo M
An Bras Dermatol; 2016; 91(5):652-654. PubMed ID: 27828643
[TBL] [Abstract][Full Text] [Related]
36. Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patients.
Laine L; Curtis SP; Cryer B; Kaur A; Cannon CP
Aliment Pharmacol Ther; 2010 Nov; 32(10):1240-8. PubMed ID: 20955443
[TBL] [Abstract][Full Text] [Related]
37. Symmetrical Drug-Related Intertriginous and Flexural Exanthema (SDRIFE) Caused by Etoricoxib.
Caralli ME; Seoane Rodríguez M; Rojas Pérez-Ezquerra P; Pelta Fernández R; De Barrio Fernández M
J Investig Allergol Clin Immunol; 2016; 26(2):128-9. PubMed ID: 27164635
[No Abstract] [Full Text] [Related]
38. Etoricoxib-induced acute generalized exanthematous pustulosis.
Mäkelä L; Lammintausta K
Acta Derm Venereol; 2008; 88(2):200-1. PubMed ID: 18311467
[No Abstract] [Full Text] [Related]
39. Bullous fixed drug eruption to etoricoxib--further evidence of intraepidermal CD8+ T cell involvement.
Duarte AF; Correia O; Azevedo R; do Carmo Palmares M; Delgado L
Eur J Dermatol; 2010; 20(2):236-8. PubMed ID: 20110201
[No Abstract] [Full Text] [Related]
40. Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema.
Sánchez-Borges M; Caballero-Fonseca F; Capriles-Hulett A
Ann Allergy Asthma Immunol; 2005 Aug; 95(2):154-8. PubMed ID: 16136765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
